Cargando…

DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?

Major depressive disorder (MDD) is a debilitating psychiatric disorder, the third leading global cause of disability. Regarding aetiopathogenetic mechanisms involved in the onset of depressive disorders, the interaction between genetic vulnerability traits and environmental factors is believed to pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Paoli, Caterina, Misztak, Paulina, Mazzini, Giulia, Musazzi, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890294/
https://www.ncbi.nlm.nih.gov/pubmed/35105292
http://dx.doi.org/10.2174/1570159X20666220201084536
_version_ 1784880920312938496
author Paoli, Caterina
Misztak, Paulina
Mazzini, Giulia
Musazzi, Laura
author_facet Paoli, Caterina
Misztak, Paulina
Mazzini, Giulia
Musazzi, Laura
author_sort Paoli, Caterina
collection PubMed
description Major depressive disorder (MDD) is a debilitating psychiatric disorder, the third leading global cause of disability. Regarding aetiopathogenetic mechanisms involved in the onset of depressive disorders, the interaction between genetic vulnerability traits and environmental factors is believed to play a major role. Although much is still to be elucidated about the mechanisms through which the environment can interact with genetic background shaping the disease risk, there is a general agreement about a key role of epigenetic marking. In this narrative review, we focused on the association between changes in DNA methylation patterns and MDD or depressive-like phenotype in animal models, as well as mechanisms of response to antidepressant drugs. We discussed studies presenting DNA methylation changes at specific genes of interest and profiling analyses in both patients and animal models of depression. Overall, we collected evidence showing that DNA methylation could not only be considered as a promising epigenetic biomarker of pathology but could also help in predicting antidepressant treatment efficacy. Finally, we discussed the hypothesis that specific changes in DNA methylation signature could play a role in aetiopathogenetic processes as well as in the induction of antidepressant effect.
format Online
Article
Text
id pubmed-9890294
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-98902942023-10-11 DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention? Paoli, Caterina Misztak, Paulina Mazzini, Giulia Musazzi, Laura Curr Neuropharmacol Neurology Major depressive disorder (MDD) is a debilitating psychiatric disorder, the third leading global cause of disability. Regarding aetiopathogenetic mechanisms involved in the onset of depressive disorders, the interaction between genetic vulnerability traits and environmental factors is believed to play a major role. Although much is still to be elucidated about the mechanisms through which the environment can interact with genetic background shaping the disease risk, there is a general agreement about a key role of epigenetic marking. In this narrative review, we focused on the association between changes in DNA methylation patterns and MDD or depressive-like phenotype in animal models, as well as mechanisms of response to antidepressant drugs. We discussed studies presenting DNA methylation changes at specific genes of interest and profiling analyses in both patients and animal models of depression. Overall, we collected evidence showing that DNA methylation could not only be considered as a promising epigenetic biomarker of pathology but could also help in predicting antidepressant treatment efficacy. Finally, we discussed the hypothesis that specific changes in DNA methylation signature could play a role in aetiopathogenetic processes as well as in the induction of antidepressant effect. Bentham Science Publishers 2022-11-15 2022-11-15 /pmc/articles/PMC9890294/ /pubmed/35105292 http://dx.doi.org/10.2174/1570159X20666220201084536 Text en © 2022 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Neurology
Paoli, Caterina
Misztak, Paulina
Mazzini, Giulia
Musazzi, Laura
DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?
title DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?
title_full DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?
title_fullStr DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?
title_full_unstemmed DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?
title_short DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?
title_sort dna methylation in depression and depressive-like phenotype: biomarker or target of pharmacological intervention?
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890294/
https://www.ncbi.nlm.nih.gov/pubmed/35105292
http://dx.doi.org/10.2174/1570159X20666220201084536
work_keys_str_mv AT paolicaterina dnamethylationindepressionanddepressivelikephenotypebiomarkerortargetofpharmacologicalintervention
AT misztakpaulina dnamethylationindepressionanddepressivelikephenotypebiomarkerortargetofpharmacologicalintervention
AT mazzinigiulia dnamethylationindepressionanddepressivelikephenotypebiomarkerortargetofpharmacologicalintervention
AT musazzilaura dnamethylationindepressionanddepressivelikephenotypebiomarkerortargetofpharmacologicalintervention